FN1+ Macrophages Drive Aggressive Sarcomatoid Differentiation and Immunotherapy Resistance in Renal Cell Carcinoma
核心洞察
FN1-expressing tumor-associated macrophages are identified as key drivers of sarcomatoid dedifferentiation in renal cell carcinoma (搜索), a highly aggressive histological variant with poor prognosis.
Single-cell multi-omics analysis reveals that FN1+ macrophages promote epithelial-to-mesenchymal transition and immunosuppressive tumor microenvironment remodeling.
The study demonstrates that FN1-mediated crosstalk between macrophages and cancer cells contributes to resistance against immune checkpoint inhibitor therapy.
A new study published in Oncogene uncovers a critical role for fibronectin 1 (搜索) (FN1)-expressing tumor-associated macrophages in driving sarcomatoid differentiation and fostering immunotherapy resistance in renal cell carcinoma (搜索) (RCC). The research, which leverages single-cell transcriptomic profiling and functional validation, provides mechanistic insight into one of the most lethal manifestations of kidney cancer.
Sarcomatoid RCC represents a final common dedifferentiation pathway across renal epithelial malignancies and is associated with rapid disease progression, limited treatment options, and poor survival outcomes. While immune checkpoint inhibitors have transformed the management of advanced RCC, patients with sarcomatoid features frequently exhibit suboptimal responses, underscoring an urgent unmet clinical need.
Single-Cell Atlas Reveals a Distinct Macrophage Subset
Through integrative single-cell analysis of RCC tumor specimens, the investigators identified a discrete population of tumor-associated macrophages characterized by high FN1 expression. These FN1+ macrophages were enriched specifically in tumors exhibiting sarcomatoid histology and were closely associated with transcriptional programs governing epithelial-to-mesenchymal transition (EMT)—a cellular process long implicated in sarcomatoid conversion of clear cell RCC.
Gene set enrichment analyses demonstrated that FN1+ macrophages display a transcriptional signature consistent with immunosuppressive polarization, including upregulation of pathways linked to tissue remodeling, extracellular matrix organization, and immune evasion. The spatial proximity of these macrophages to dedifferentiating tumor cells suggests a paracrine crosstalk that actively promotes the sarcomatoid phenotype.
FN1 as a Mediator of Tumor–Immune Crosstalk
Fibronectin, a multifunctional glycoprotein of the extracellular matrix, has been previously implicated in cancer metastasis and wound healing. In the context of RCC, the study shows that macrophage-derived FN1 engages integrin receptors on cancer cells, activating downstream FAK/Src signaling cascades that reinforce mesenchymal gene expression programs. This molecular dialogue between FN1+ macrophages and tumor cells establishes a positive feedback loop that perpetuates sarcomatoid dedifferentiation.
The findings align with broader pan-cancer observations that myeloid cells pave the metastatic road through matrix remodeling and immunosuppressive conditioning of the tumor microenvironment. Notably, the FN1–integrin axis has been independently validated in breast cancer models, where fibroblast activation protein-positive cancer-associated fibroblasts induce M2-like macrophage polarization via FN1–integrin α5β1 interactions.
Immunotherapy Resistance and Prognostic Implications
The study further demonstrates that FN1+ macrophage infiltration correlates with diminished responsiveness to PD-1 blockade in advanced RCC. By analyzing cohorts of patients treated with immune checkpoint inhibitors, the researchers found that high FN1+ macrophage signatures were associated with reduced progression-free survival and lower objective response rates.
This observation is consistent with the broader understanding that the immune contexture—the composition, density, and functional orientation of tumor-infiltrating immune cells—profoundly influences cancer prognosis and treatment outcomes. The immunosuppressive milieu orchestrated by FN1+ macrophages may represent a barrier that limits the efficacy of T-cell-centric immunotherapies.
Toward Biomarker-Driven Stratification
The identification of FN1+ macrophages as a determinant of aggressive biology and therapeutic resistance carries immediate translational relevance. Incorporating FN1+ macrophage signatures into existing prognostic models—such as the International Metastatic RCC Database Consortium criteria—could refine risk stratification in the immunotherapy era, where traditional models may require re-evaluation.
Furthermore, therapeutic targeting of the FN1–integrin axis or reprogramming of FN1+ macrophages toward an immunostimulatory phenotype represents a rational strategy to overcome resistance. The study adds to a growing body of evidence that the tumor microenvironment, and tumor-associated macrophages in particular, constitutes a clinically relevant therapeutic frontier in RCC.
Study Context and Limitations
The research builds upon a robust foundation of single-cell investigations that have mapped the RCC immune landscape, including studies by Krishna et al., Obradovic et al., and Li et al., which collectively established the heterogeneity of myeloid compartments in kidney tumors. The current work extends these findings by functionally linking a specific macrophage subset to a discrete and clinically devastating histologic phenotype.
Limitations acknowledged by the authors include the retrospective nature of clinical correlations and the need for prospective validation in independent cohorts. Additionally, the precise molecular mechanisms by which FN1+ macrophages are recruited and maintained within the sarcomatoid niche warrant further investigation.